The International Society for Pharmacoepidemiology (ISPE) gratefully acknowledges the generous support of the following organizations and institutions. Their contributions and memberships helped to enhance the scientific program content and increase attendance at the ICPE 2006. Thank you.

**EXHIBITORS**

Charles River Laboratories Clinical Services
DrugLogic
GlaxoSmithKline
GPRD
i3 Drug Safety
IPCI Erasmus University Medical Center
John Wiley & Sons
MedTel Outcomes, LLC
PharmIdeas Research
PHARMO Institute
Phase Forward/Lincoln Technologies
RTI Health Solutions
Sentrx
Uniform Data System
United BioSource Corporation
The Uppsala Monitoring Centre
Wolters Kluwer Health, Adis

**ACADEMIC SHOWCASE / WELCOME RECEPTION SPONSORS**

Boston Collaborative Drug Surveillance Program, Boston University
Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
Drug Safety Research Unit
Pharmacoepidemiology and Therapeutics Program, Utrecht Institute for Pharmaceutical Sciences (UIPS)
Pharmacy Practice & Administration Division, College of Pharmacy, University of Texas at Austin
Slone Epidemiology Center, Boston University
The Pharmaceutical Health Services Research Graduate Program at the University of Maryland, Baltimore School of Pharmacy

**ANNUAL MEETING SPONSORS**

▲ DIAMOND: $25,000
- i3 Drug Safety

▲ PLATINUM: $12,000
- John Wiley & Sons
- Novartis
- Pfizer

▲ GOLD: $6,000
- Amgen
- Eli Lilly and Company
- GlaxoSmithKline
- Merck & Co., Inc. — USA
- RTI Health Solutions
- Procter & Gamble
- United BioSource Corporation
- Wyeth Research

▲ SILVER: $3,000
- Boehringer Ingelheim Pharmaceuticals
- Genzyme

▲ BRONZE: $1,500
- Allergan
- GPRD
- HealthCore
- Outcome

**IN THIS PROGRAM:**

22nd ICPE Agenda
Wednesday ........................................ 7
Thursday .......................................... 8
Friday ................................................... 9
Saturday ............................................. 16
Sunday .................................................. 24

22nd ICPE Posters
Poster Presentation Guidelines .................. 30
Poster Session A .................................. 31
Poster Session B ................................ 39
Poster Session C ................................ 45

22nd ICPE Abstract Index
Abstract Index ...................................... 52
AGENDA | Wednesday, August 23

11:00–Noon
- ISPE Finance Committee (Hotel Vila Gale Opera)

Noon–1:00PM
- Orientation Session for New ISPE Board Members (Hotel Vila Gale Opera)

Noon–5:30PM
- Registration (Registration Desk/Ground Floor/Congress Centre)

1:00–5:30PM
- ISPE Board of Directors Meeting (Hotel Vila Gale Opera)

PRE-CONFERENCE EDUCATIONAL SESSION

1:30–5:30PM
- Speakers Ready Room/AV (Rooms 1.09 + 1.14)

- Introduction to Pharmacoepidemiology (AUD 3 & 4)
  Registration required; included as part of full meeting registration.
  Chair: Andrew McAfee
  Andrew Bate, Spontaneous Reporting
  Andrew McAfee, Cohort Studies
  Michael Lewis, FISPE, Case-Control Studies
  Jacques LeLorier, FISPE, Confounding by Indication

7:30–10:00PM
- ISPE Board of Directors Dinner (By invitation)

Badges
All attendees at ICPE 2006 must wear their name badges to ALL events. A badge will be needed for admission to meeting related functions such as scientific sessions, the exhibit/poster hall, and social events. Badges will be included in the registration packet material. In some cases, tickets will be required.

Badge Legend
Student – Yellow
New Member – Blue Dot
One Day Attendee – Red

Room Legend
AUD = Auditorium
PAV = Pavilion

FUTURE MEETINGS

2006
First Asian International Society for Pharmacoepidemiology Conference combined with the Third China Shanghai International Conference on Rational Drug Use and Pharmacoepidemiology
September 26–29, 2006
Shanghai & Lu Mountain, Jiangxi province, China

2007
ISPE Mid-Year Meeting
April 21–22, 2007
Hotel NH Grand Hotel Krasnapolsky
Amsterdam, The Netherlands
(Meeting held in conjunction with the Pharmaceutical Sciences World Congress)

Saturday, April 21
8:30–12:30pm Introduction to Pharmacoepidemiology
12:30–5:30pm ISPE Board of Directors Meeting

Sunday, April 22
8:30–1:30pm Advanced Topics in Pharmacoepidemiology
1:30–5:30pm ISPE Scientific Program Committee –2007

Monday, April 23
ISPE Contributed Symposium at the PSWC
RAI Congress Centre
www.fip.org/PSWC

2008
ISPE Mid-Year Meeting
April TBD, 2008
Boston, Massachusetts, USA

24th ICPE
August TBD
Copenhagen, Denmark

2009
ISPE Mid-Year Meeting
April, TBD
Stockholm, Sweden

25th ICPE
 Providence, Rhode Island, USA

Visit the ISPE website, www.pharmacoepi.org, for meeting updates and information.
AGENDA | Thursday, August 24

8:00-6:00PM
registrations (Registration Desk/Ground Floor/Congress Centre)

8:00-5:00PM
Speakers Ready Room/AV (Rooms 1.09 + 1.14)

PRE-CONFERENCE EDUCATIONAL SESSIONS

8:30-Noon
Introduction to Therapeutic Risk Management: Evaluating the Effectiveness of Risk Management Programs (AUD 3 & 4)
* Admission by ticket only. Tickets will be included in registration for those who registered for this session.

Elizabeth Andrews, FISPE, Overview of Risk Management and the Role of Evaluation
Javier Cid, Selected Examples of Risk Management Programs and Evaluation
Judith Jones, FISPE, Workshop for Participants to Develop an Evaluation Plan

8:30 - Noon
Skills Workshop – Students Only* (Room 3A)
* Registration required; included as part of full meeting registration

• How to Design an Effective Presentation for Your Internal and External Stakeholders [649]
Shubh L Sethi, Matthew W Reynolds. (United States)

• How Did I Get Here?
Roundtable discussion of career opportunities within pharmacoepidemiology
Moderator: Marieke Schoonen
Panelists:
Peter Egger, European Industry Perspective
Tjeerd van Staa, European Regulatory Agency Perspective
Stephen J. Evans, Academic Perspective
TBA, Consulting Perspective

Noon - 1:30PM
Lunch – on your own (available at Congress Centre)

Noon-1:30PM
ISPE Education Committee (Room 1.05)

Noon-1:30PM
Orientation to ISPE - New Members/Student Prize Winners/ Scholarship Recipients (Espaço Tejo Restaurant/First Floor/Congress Centre)

Noon - 5:00PM
Exhibitor Move-in (PAV 5)
AGENDA | Friday, August 25

8:00-9:00AM
- Poster Session A Set-up (PAV 4)

8:00-5:00PM
- Exhibits (PAV 5)
- Speakers Ready Room/AV (Rooms 1.09 + 1.14)

8:00-6:00PM
- Registration (Registration Desk/Ground Floor/Congress Centre)

9:00-10:30AM
OPENING SESSION (AUD 1)
- Welcome
  Bert Leufkens, FISPE, Chair, Scientific Program Committee
  Vasco de Jesus Maria, Chair, Local Host Committee
- Presidential Address
  Sean Hennessy, FISPE, ISPE President
- Keynote Address
  Richard Laing, WHO Department of Policy and Standards for Medicines, Geneva Switzerland

10:30-11:00AM
- Break/Posters/Exhibits (PAV 4/5)
  Sponsored by RTI Health Solutions

---

Pharmacoepidemiology for Public Health

RTI Health Solutions®

THE DATABASE CHALLENGE

Rely on our experience to select the right databases for your epidemiological studies.

Contact
Research Triangle Park, NC, USA
US 1.800.262.3011/1.919.541.6000 x1541
Manchester, UK
UK 44(0)161.232.3400
www.rtihsa.org
rtihealthsolutions@rti.org

Visit RTI Health Solutions’ exhibit booth to learn how we can help you design and implement your database studies. Test your knowledge of European databases and win a prize.

LEADING RESEARCH... MEASURES THAT COUNT
11:00–12:30PM
CONCURRENT SESSIONS

Risk Assessment: Contributed Papers (AUD 2)
Moderators: Byung-Joo Park, FISPE & Corinne de Vries

11:00AM
Corticosteroids and the Risk of Atrial Fibrillation [2]
Cornelis S van der Hooft, Jan Heeringa, Guy G Brusselle, Albert Hofman, Jacqueline C Wittenma, Herre Kingma, Miriam C Sturkenboom, Bruno H Stricker. (Netherlands)

11:15AM
Increased Risks of End-Stage Renal Disease Associated with Prescribed Chinese Herb Medicines: A Follow-Up of the Representative 200,000 People in Taiwan, 1997-2002 [3]
Ming-Nan Lai, Jung-Nien Lai, Pau-Chung Chen, Wei-Lum Tseng, Ya-Yin Chen, Jung-Der Wang. (Taiwan)

11:30AM
Mark L Ma, Meng Tan, Kenneth Hornbuckle. (United States)

11:45AM
Angiotensin Converting Enzyme – Inhibitors and Angiotensin II Receptor Antagonists and the Risk of Acute Pancreatitis: A Population-Based Case-Control Study [5]
Christiane Gasse, Jacob Jacobsen, Mette Nørgaard, Henrik T Sørensen, Søren P Johnsen. (Denmark)

12:00PM
Oral Glucocorticoids and Risk of Suicide: A Cohort Study in the General Practice Research Database [6]
Patrick C Souverein, Niels Speksnijder, Tjerd P van Staa, Berend Olivier, Toine CG Egberts, Hubert GM Leufkens. (Netherlands)

12:15PM
Prescription of beta-Blockers in Patients with Advanced Heart Failure and Preserved Left Ventricular Ejection Fraction. Implications for Survival [7]
Daniela Dobre, Dirk J Van Veldhuizen, Mike JL Delongste, Carolein Lucas, Ger Cleuren, Robbert Sanderman, Adelita V Ranchor, Flora M Haaijer-Ruskamp. (Netherlands)

Y Moride, L Lynd, L Abenhaim, N Moore, X Kurz, C Hartford. (Canada)

WORKSHOP: Prescribing Quality Indicators Based on Administrative Data: Grasping the Essence or Scratching the Surface? [20] (AUD 3)
B Wettermark, M Andersen, V Vlahovic-Palcevski, R Vander Stichele, F Haaijer-Ruskamp, P Mol. (Netherlands)

WORKSHOP: Designed Delays vs Rigorous Pragmatic Trials: How Much Should We Allow the Gold Standard of Evidence To Be Tarnished? [21] (AUD 4)
Malcolm Maclure, Colin Dormuth, Sebastian Schneeweiss, Tom MacDonald. (United States)
### Birth Defects: Contributed Papers (AUD 6)

**Moderators:** Abraham Hartzema, FISPE & Filipa Costa

**11:00AM**

Late Pregnancy Use of Non-Steroidal Anti-Inflammatory Drugs and Risk for Persistent Pulmonary Hypertension of the Newborn [8]
Sonia Hernández-Díaz, Martha M Werler, Carol Louik, Linda J Van Marter, Allen A Mitchell. (United States)

**11:15AM**

Risk of Congenital Malformations in Pregnant Users of Non-Steroidal Anti-Inflammatory Drugs [9]
Benjamin D Ofori, Driss Oraichi, Anick Berard. (Canada)

**11:30AM**

Exposure to Mirtazapine during Pregnancy: A Prospective Comparative Study of Birth Outcomes [10]
Josephine Djulus, Gideon Koren, Thomas Einarson, Lynda Wilton, Saad Shakir, Orna Diav-Citrin, Deborah Kennedy, Sharon Lavigne, Marco De Santis, Adrienne Einarson. (Canada)

**11:45AM**

Increase of Antidepressants’ Use in Pregnancy in the Netherlands [11]
Marian K Bakker, Paul B van den Berg, Pieterernel Kolling, Lolkje TW de Jong-van den Berg. (Netherlands)

**12:00PM**

Paroxetine in the First Trimester of Pregnancy and the Prevalence of Congenital Malformations [12]
J Alexander Cole, Eva W Ng, Sara A Ephross, Irene S Cosmatos, Alexander M Walker. (United States)

### Respiratory Outcomes: Contributed Papers (AUD 8)

**Moderators:** Jose Marinho Falcao & Keith Beard, FIPSE

**11:00AM**

Annual Influenza Vaccination in Community Dwelling Elderly and the Risk of Lower Respiratory Tract Infections or Pneumonia [14]
Bettie CG Voordouw, Miriam CJM Sturkenboom, Jeanne P Dieleman, Theo Stijnen, Johan van der Lei, Bruno HCh Stricker. (Netherlands)

**11:15AM**

The Control and Severity of Asthma during Pregnancy and the Incidence of Asthma in the Offspring [15]
Marie-Josee Martel, Evelyne Rey, Marie-France Beauchesne, Jean-Luc Malo, Sylvie Perreault, Amelie Forget, Lucie Blais. (Canada)

**11:30AM**

Assessing the Time-Dependency Nature of Comorbidity Influence in COPD [16]
Victor A Kiri, James Oyee. (United Kingdom)

**11:45AM**

Effectiveness of Combination Therapy in Asthma [17]
Lucie Blais, Catherine Lemièere, Claudine Marceau, Sylvie Perreault, Djamal Berbiche. (Canada)

**12:00PM**

Use of beta-2 Agonists and Risk of Hip/Femure Fracture: Associations with Daily and Cumulative Dose in a Population-Based Case-Control Study [18]
Frank de Vries, Sander Prouwels, Madelon Bracke, Jan-Willem Lammers, Bert Leufkens, Mira Zuidgeest, Tjeerd van Staa. (Netherlands)

**12:15PM**

Theophyllines, Long-Acting b2-Agonists and Inhaled Corticosteroids and the Risk of Mortality among Patients with Chronic Obstructive Pulmonary Disease [19]
Marie-Christyne Cyr, Marie-France Beauchesne, Catherine Lemièere, Lucie Blais. (Canada)
AGENDA | Friday, August 25

12:30 - 2:00PM
- Lunch/Poster Session A/Exhibits (PW 4/5)
- EuroDURG General Assembly (AUD 2)
- ISPE Committee/Council Meetings
  Lunches will be available in meeting rooms. *Open to all participants.
- Public Policy Committee (Room 1.08)
- Student Council (Room 1.07) *All students invited to attend
- Public Relations Committee (Room 1.06)
- Bylaws & Policies Committee (Room 1.05)
- Fellowship & Awards Committee (Room 1.04)

2:00 - 3:30PM
CONCURRENT SESSIONS

- SYMPOSIUM: Control of Unmeasured Confounding [22]
  (AUD 1)
  Til Stürmer, Jay S Kaufman, Alan Brookhart, Michal Abrahamovicz, Robert J Glynn,
  Kenneth J Rothman. (United States)

- Risk Management: Contributed Papers (AUD 2)
  Moderators: Stephen J.W. Evans & Priya Bahri

  2:00PM
  Adverse Drug Reactions in Children: A Multicenter Study in Italy [23]
  Francesca Menniti-Ippolito, Roberto Da Cas, Monica Bolli, Annalisa Capuano,
  Giuseppe Traversa, The Multicenter Study Group on Adverse Drug Reactions in
  Children. (Italy)

  2:15PM
  Prenatal Testing Prior to Enrollment in Pregnancy Exposure Registries [24]
  Susan Roberts, Deborah Covington, Peggy Doi. (United States)

  2:30PM
  An Evaluation of a Sticker-Based RMP for Isotretinoin [25]
  Carla M Van Bennekom, Allen A Mitchell. (United States)

  2:45PM
  No Increased Risk of Abdominal or Pelvic Surgery Associated with Tegaserod
  Exposure: The Zelnorm™ Epidemiological Study [26]
  John D Seeger, Sherry Quinn, Fabio Lievano, Elena Rivero, David L Earnest, Michael
  Shetzline, William Holden, Alexander M Walker. (United States)

  3:00PM
  Safety-Related Drug Labeling Changes in the United States and Germany [27]
  Edeltraut Garbe, René Schade, Frank Andersohn. (Germany)

  3:15PM
  Does Risk Communication Have a Direct Impact in the Overall
  Pharmacovigilance Activities? [28]
  M Arriegas, F Bragança, R Carmona, A Pêgo, P Roque, J Silva, I Sobral. (Portugal)

  Nicholas D Moore, Elisabeth Loupi, Brian Edwards, Kees VanGrootheest. (France)

- Workshop: Methodologies and Platforms for Policy
  Evaluation of Pharmaceutical Interventions [42] (AUD 4)
  Pieter Stolk, Sebastian Schneeweiss, Robert H Vander Stichele, Eibert R Heerdink.
  (Netherlands)
Psycotropics in Children: Contributed Papers (AUD 6)
Moderators: Adrienne Einarson & Emilio Sanz

2:00PM
Psycotropic Medication Use among Publicly Insured U.S. Youth [29]

2:15PM
Sengwee Toh. (United States)

* Student Award – Best Drug Utilization Abstract

2:30PM
Drug Utilization Study of Methylphenidate, Dexamfetamine and Atomoxetine in Patients Aged 15-21 Years in UK Primary Care Using the General Practice Research Database (GPRD) [31]
Suzanne McCarthy, Macey Murray, Ian Wong. (United Kingdom)

2:45PM
Stimulant Utilization in Children and Adolescents in 4 Countries [32]
Julie M Zito, Daniel J Safer, Lolkje TW de Jong-vandenBerg, Jorg M Fegert, Katrin Janhsen, Corinne S de Vries, Gerd Glaeske. (United States)

3:00PM
Effect of Government Regulatory Changes on SSRI Prescriptions in Children [33]
Benji T Kurian, Patrick G Arbogast, Wayne A Ray, D C Fuchs, William O Cooper. (United States)

3:15PM
Antidepressant Use among Children and Adolescent in Finland: A Register- Linkage Study, 1994-2003 [34]
Sinikka Silvo, Tiina Sevon, Jari Haukka, Elina Hemminki, Ilmo Keskimaki, Sonja Lumme, Alison McCallum, Kristian Wahlbeck. (Finland)

Genes and Biologicals: Contributed Papers (AUD 8)
Moderators: Henrique de Barros & Joanna F Haas

2:00PM
Diuretic–Gene Interactions and the Risk of Myocardial Infarction and Stroke [35]
Hedi Schelleman, Olaf H Klungel, Jacqueline CM Witteman, Cornelia M van Duin, Albert Hofman, Monique MB Breteler, Anthonius de Boer, Bruno HCh Stricker. (Netherlands)

2:15PM
Association between CV Outcomes, Diuretic Use and the a-Adducin Gene; Results from the INternational Verapamil SR-Trandolapril Study (INVEST) [36]
Tobias Gerhard, Yan Gong, Amber L Beitelshees, Rhonda M Cooper-DeHoff, Julie A Johnson. (United States)

2:30PM
Non-Oncologic Use of Human Recombinant Erythropoietin in Hospitalized Patients [37]
Charles A Morris, Michael A Fischer, Wolfgang C Winkelmayer, Jerry Avorn. (United States)

2:45PM
ABCB1 G2677T/A and C3435T Polymorphisms and the Risk of Drug Induced Acute Agranulocytosis [38]
Frank Andersohn, Elisabeth Bronder, Andreas Klimpel, Edeltraut Garbe. (Germany)

3:00PM
Tumor Necrosis Factor–a Antagonist Use and Cancer in Patients with Rheumatoid Arthritis [39]
Soko Setoguchi, Daniel H Solomon, Michael E Weinblatt, Jeffrey N Katz, Jerry Avorn, Robert J Glynn, E Francis Cook, Greg Carney, Sebastian Schneeweiss. (United States)

3:15PM
Absence of an Interaction between the Angiotensin Converting Enzyme (ACE) Insertion–Deletion Polymorphism and Pravastatin on Cardiovascular Disease in High-Risk Hypertensives: The GenHAT Study [40]
Anke H Maitland-van der Zee, Eric Boerwinkle, Donna K Arnett, Barry R Davis, Catherine Leendecker-Foster, Michael B Miller, Olaf H Klungel, Charles E Ford, John E Eckfeldt. (Netherlands)

3:30-4:00PM
Break/Posters/Exhibits (PAV 4/5)
CONCURRENT SESSIONS

SYMPOSIUM: Clinical Trial Simulation in Pharmacoepidemiology [43] (AUD 1)
Sonia Hernández-Díaz, Wayne A Ray, Alexander M Walker, Miguel A Hernán. (United States)

Pharmacovigilance: Contributed Papers (AUD 2)
Moderators: Bruno Stricker & Marques Batel

4:00PM
Data Mining in the US FDA Adverse Event Reporting System (AERS): Depression/Suicidality and Unexpected Adverse Events with Anti-Obesity Drugs [44]
F Patrick Delisle, Kenneth Hornbuckle, Rebecca Noel. (United States)

4:15PM
Severe Necrotising Soft Tissue Infections and Necrotizing Fasciitis and NSAlDs: A Study in the French Pharmacovigilance Database [45]
Christelle Souyri, Pascale Olivier, Maryse Lapeyre-Mestre. (France)

4:30PM
Intervention To Improve Adverse Drug Event Reporting: A Cluster-Randomized Trial among Portuguese Physicians [46]
Teresa Herdeiro, Adolfo Figueiras, Manuela Pinto, Inês Vaz, Jorge Polónia. (Portugal)

4:45PM
A New Automatic Signal Detection Method in Pharmacovigilance: A Bayesian Multiple Comparisons Setting [47]
Ismail Ahmed, Françoise Haramburu, Annie Fourrier, Frantz Thiessard, Bernard Bégaud, Pascale Tubert-Bitter. (France)

5:00PM
Evolution of Hospitalizations Related to Poisoning Events in Portugal [48]
José P Guerreiro, José Giria, Filipa Costa, Ermelindo Fontes, Ana C Miranda. (Portugal)

5:15PM
Are Inappropriate Medications the Major Cause of Adverse Drug Reactions in the Elderly? [49]
Marie-Laure Laroche, Jean-Pierre Charmes, Louis Merle. (France)

WORKSHOP: Applications of Standardised MedDRA Queries (SMQs) in Drug Safety and Pharmacoepidemiology [62]
(GAUD 3)
Gottfried Kreutz, Judith K Jones, Norbert Paeschke, Sabine Luik. (United States)

WORKSHOP: Pharmacoepidemiology and Biotechnology Products [63] (AUD 4)
Joanna F Haas, Rhonda L Bohn, Kathryn Starzyk, Stella Blackburn, Bettie Voordouw, John Ferguson, Nancy Dreyer. (United States)

Women’s Health: Contributed Papers (AUD 6)
Moderators: Saad Shakir & Annlouise Assaf

4:00PM
Natural History of Newly Diagnosed Patients with Venous Thromboembolism [50]
Consuelo Huerta, Mary-Ann Wallander, Saga Johansson, García Rodriguez Luis Alberto. (Spain)

4:15PM
The Risk of Venous Thromboembolism (VTE) in Oral Contraceptives: A New Lesson [51]
Lothar AJ Heinemann, Anita Assmann, Juergen C Dinger. (Germany)

4:30PM
Factors Influencing Return to Fertility after Use of Oral Contraceptives [52]
Ilka Schellschmidt, Do Minh Thai, Sabine Moehner, Juergen C Dinger. (Germany)

4:45PM
Cyproterone Acetate + Ethinyloestradiol and the Risk of Depression [53]
Helen E Seaman, Julia Snowball, Corinne S de Vries. (United Kingdom)

5:00PM
Hormone Therapy Re-Initiation and First-Time Initiation by Type, Dose and Route, after the Women’s Health Initiative [54]
Katherine M Newton, Diana SM Buist, Onchee Yu, Cynthia L Hartsfield, Susan E Andrade, Feifei Wei, Maureen T Connelly, K Arnold Chan. (United States)

5:15PM
The European Active Surveillance Study on Oral Contraceptives (EURAS-OC): Final Results after More Than 130,000 WY of Observation [55]
Juergen C Dinger, Anita Assmann, Lothar Aj Heinemann. (Germany)
**AGENDA | Friday, August 25**

### Infections/Pandemic Flu: Contributed Papers (AUD 8)

**Moderators:** Miles Braun, FISPE & Harry Seifert

- **4:00PM**
  Evaluating Reports of Fever after Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B, Inactivated Poliovirus Vaccine Combined (DTaPHE) from the U.S. Vaccine Adverse Event Reporting System (VAERS) [56]
  Soju Chang, John Iskander, Karen Farizo, M Miles Braun, Robert Ball. (United States)

- **4:15PM**
  An Evaluation of the Effects of Gatifloxacin on Glucose Homeostasis [57]
  Ahunna Onyenwenyi, Almut Winterstein, Randy Hatton. (United States)

- **4:30PM**
  Antibacterial Drugs and the Risk of Infection with Methicillin Resistant Staphylococcus Aureus (MRSA) in the Community [58]
  V Schneider, S Dial, J A Delaney, A Dascal, S Suissa. (Canada)

- **4:45PM**
  Anti-TNF-alpha Therapy and the Risk of Severe Bacterial Infections [59]
  Sebastian Schneeweiss, Soko Setoguchi, Michael E Weinblatt, Jeffrey N Katz, Jerry Avorn, Paul E Sax, Raia Levin, Daniel H Solomon. (United States)

- **5:00PM**
  Annual Influenza Vaccination and Risk of Sudden Cardiac Death in Community Dwelling Elderly Persons [60]
  Bettie CG Voordouw, Sabine SJM Straus, Miriam CJM Sturkenboom, Jeanne P Dieleman, Theo Stijnen, Johan van der Lei, Bruno HCh Stricker. (Netherlands)

- **5:15PM**
  Quinolone Use and the Risk of Community-Acquired Clostridium difficile in the United Kingdom [61]
  J A Delaney, Sandra Dial, Alan N Barkun, Samy Suissa. (Canada)

### 5:30-6:30PM

- **ISPE Council Meetings**
  *Open to all participants.

- **Academic Council (AUD 2)**

- **Industry Council (AUD 6)**

- **Government Council (AUD 8)**

- **EuroDURG Executive Committee (Room 1.1)**

### 6:30-8:30PM

#### EXTERNALLY FUNDED SYMPOSIUM*

- **GPRD Users Group Meeting** (Hotel Vila Gale Opera)
  *Open to all participants. Not part of the ICPE Scientific Program.

  *This symposium provides an opportunity to learn about the latest developments in GPRD, including new data linkages, the new possibility of conducting randomized studies within GPRD, and a novel approach in risk-benefit assessment. A canapé reception to follow.*

- **PDS Editorial Board** (Pestana Palace)
  (By invitation)

### 7:30-10:00PM

- **Student Social Event**
  Check bulletin board at Registration Desk for details.
  Open to all students.
  Organized by the ISPE Student Council
AGENDA | Saturday, August 26

JOINT ISPE–EURODURG DAY

7:30-8:30AM

▼ Special Interest Group – Drug Utilization (Hotel Vila Gale Opera)
*Open to all participants.

8:00-9:00AM

▼ Poster Session B Set-up (PAV 4)

8:00-5:00PM

▼ Exhibits (PAV 5)

▼ Speakers Ready Room/AV (Room 1.09 + 1.14)

8:00-6:00PM

▼ Registration (Registration Desk/Ground Floor/Congress Centre)

PLENARY SESSION

9:00-10:30AM

Balancing Patient Safety and Pharmaceutical Innovation: Fostering the Lisbon Objectives (AUD 1)
Moderator: Fernand Sauer

Vasco de Jesus Maria, Is ‘Lisbon’ Still Driving the EU Medicines Policy Agenda?

Albert van der Zeijden, Are Patients Happy with so much Focus on Safety?

Susana Perez–Gutthann, FISPE, How is Industry Balancing Innovation and Patient Safety?

10:30-11:00AM

▼ Break/Posters/Exhibits (PAV 4/5)

Rewarding work

For more information please email: EURD_UKcareers@amgen.com

AMGEN

“Company of the Year” FORBES MAGAZINE 2004

“One of the Best Places to Work in Industry” THE SCIENTIST 2004 (ranked in the top five)

“A Top Employer in the Biotechnology and Pharmaceutical Industry” SCIENCE MAGAZINE 2005 (ranked in the top five)

“One of the 100 Best Companies to Work for in America” FORTUNE MAGAZINE 2006 (for the seventh time)

“One of the Top 100 Best Companies to Work For in the UK” THE SUNDAY TIMES 2006
I want to share my expertise.

You can at AstraZeneca. As a global pharmaceutical industry leader, AstraZeneca has created a work environment that cultivates talent and rewards success. We offer competitive compensation and benefits, a commitment to professional development, and the opportunity to be part of an exciting, dynamic workplace.

Among our many awards we have been recognized in 2005 as one of the Top Employers by Science magazine and one of the 100 Best Employers for Working Mothers by Working Mother magazine. AstraZeneca embraces diversity, innovation and creativity — pushing the boundaries of conventional thought to make our ideas come to life.

To apply, please submit your resume via email to opportunities.mailbox@astraZeneca.com and reference source code 11436635 in the Subject line.

We have the following United States based career opportunity available in our Wilmington, Delaware location.

Assoc. Director/Director/Sr. Director, Epidemiology

Working within the Medical Science group, this individual will provide epidemiology expertise for one of several therapeutic areas. Will work with senior staff on study design, analysis, data interpretation, and reporting functions related to clinical trials; ensure clinical studies operate with the highest safety standards and are in compliance with all GCP and regulatory requirements; perform in-depth epidemiological literature reviews; and initiate and monitor epidemiological research conducted by external scientific groups.

Physicians (Epidemiologists) must have two or more years of drug development experience within a related industry or in academia. Significant experience designing clinical trials and interpreting results, and a comprehensive understanding of biostatistics and safety reporting. Scientists (PhD) in epidemiology should possess at least 5 years' experience as an epidemiologist in a healthcare environment and sustained productivity in epidemiological research relevant to drug discovery.

www.AstraZenecaCareers.com
11:00 – 12:30 PM

CONCURRENT SESSIONS

ISPE-EuroDURG SYMPOSIUM (AUD 1)
Global Assessment of the Contribution of Drug Utilization Research to Public Health
Co-Chairs: Frank May, FISPE & Robert Vander Stichele
Speakers: Flora Haaijer-Ruskamp, Europe; Richard Laing, Developing World; Junichi Kawakami, Japan; Jerry Avorn, FISPE, US/Canada; Lynn Weekes, Australia

Methods: Contributed Papers (AUD 2)
Moderators: Tjeerd van Staa & Alexander M. Walker, FISPE

11:00AM
Mixed Effect Poisson Regression with Empirical Bayes Random Effect Estimation: Application to Opioid Analgesic Abuse in the US [64]
William Irish, Meredith Smith, Jianmin Wang, Rick Dart. (United States)

11:15AM
Pharmacologic Interventions for the Prevention of Alzheimer’s Disease: An Example of Reverse Protopathic Bias [65]
Linda E Levesque, JAC Delaney, Mahyar Etemian, Samy Suissa. (Canada)

11:30AM
Randomized Experiments Versus Observational Studies? The Case of Antiretroviral Therapy and AIDS [66]
Miguel A Hernan, Stephen R Cole. (United States)

11:45AM
Nested Case-Control Validation of Results of the Zelnorm™ Epidemiological Study [67]
John D Seeger, Najat Ziyadeh, Fabio Lievano, Elena Rivero, David L Earnest, Michael Shetzline, William Holden, Alexander M Walker. (United States)

12:00 PM
Stratified Case-Cohort Design in Pharmacoepidemiological Studies [68]
Akira Wakana, Kiyoshi Kubota. (Japan)

12:15PM
Risk Adjusted Sequential and Longitudinal Monitoring Drug Performance Using GPRD [69]
Mark L Ma, Kenneth Hornbuckle, Simon Voss, Xiao Yu. (United States)

WORKSHOP: Willingness To Accept Risk-Benefit Tradeoffs: Pharmacoepidemiology Meets Preference Measurement [77]
F Reed Johnson, Teresa Kauf, Elizabeth B Andrews. (United States)

Antipsychotics: Contributed Papers (AUD 6)
Moderators: Antoine Egberts & Julie Zito

11:00AM
Antipsychotic Use and the Development of Cardiovascular Conditions in the Elderly [70]
Philip S Wang, Sebastian Schneeweiss, Soko Setoguchi, Jerry Avorn, Helen Mogun, Niteesh Choudhry, M Alan Brookhart. (United States)

11:15AM
The Use of Atypical and Conventional Antipsychotics and the Risk of Acute Pancreatitis: A Population-Based Case-Control Study [71]
Christian Gasse, Jacob Jacobsen, Mette Nørgaard, Preben B Mortensen, Søren P Johnsen, Henrik T Sørensen. (Denmark)

11:30AM
Risk of Stroke during Treatment with Atypical and Conventional Antipsychotics: A Population-Based Study in the UK [72]
Annalisa Rubino, Stephen J Evans, Liam Smeeth. (United Kingdom)

11:45AM
Use of Antipsychotics and Risk of Hip/Femur Fractures: A Population Based Case-Control Study [73]
Sander Poulwels, Frank de Vries, Antoine CG Egberts, Bert GM Leufkens, Tjeerd P van Staa. (Netherlands)

12:00PM
Early Effects of an FDA Advisory Regarding Antipsychotics Medications on U.S. Medicaid Prior Authorization Programs [74]
Jennifer Polinski, Michael Fischer, Amber Servi, Elizabeth Robinson, Philip Wang. (United States)

12:15PM
Anti-Psychotic Drugs and the Risk of Acute Urinary Retention [75]
Katia MC Verhamme, Jeanne P Dieleman, Marc Van Wijk, Johan van der Lei, Ruud Bosch, Bruno HCh Stricker, Miriam CJM Sturkenboom. (Netherlands)
SYMPOSIUM: Increased Transparency To Improve the Credibility of Pharmacoepidemiologic Studies Submitted to Regulatory Agencies and Journals? [76] (AUD 8)
Michael N Cook, Robert C Nelson, Sean Hennessy, Julie E Buring. (United States)

12:30–2:00PM
Lunch/Poster Session B/Exhibits (PAV 4/5)

12:30–2:00PM
EuroDURG Poster Walk (PAV 4)
*Open to all participants.

ISPE Committee Meetings
Lunches will be available in meeting rooms.
*Open to all participants.

Development (Room 1.08)
Membership (Room 1.07)
Global Development (Room 1.06)
Publications (Room 1.05)

For 100 years, patients first.

Merck is a global research-driven pharmaceutical company dedicated to putting patients first in all we do. That philosophy was first articulated by George Merck and it still guides us today.

For nearly 100 years, Merck has discovered, developed, manufactured and marketed novel medicines and vaccines that have delivered true advances in patient care for people around the world. We continue to do the same today.

As part of our ongoing commitment to patients, Merck devotes extensive efforts to get our medicines to those who need them regardless of their ability to pay for them and we make free, unbiased health information available to everyone.

For more information, visit www.merck.com

Where patients come first
AGENDA | Saturday, August 26

2:00–3:30PM
ANNUAL MEETING & AWARDS CEREMONY
Open to all participants. (AUD 1)

• Annual Meeting of ISPE Members
  Sean Hennessy, FISPE, ISPE President
  Frank May, FISPE, ISPE Vice President/Finance

• Awards Ceremony

 ICPE 2006
  Ana Paula Martins, Local Host Committee
  Bert Leufkens, FISPE, Chair, 2006 Scientific Program Committee

Student Awards
Presented by Bert Leufkens, FISPE, Chair, 2006 Scientific Program Committee

Best Drug Utilization Abstract: Sengwee Toh, Harvard University School of Public Health. National Trends in the Diagnosis of Attention Deficit/Hyperactivity Disorder and Use of Stimulants among Children in the United States

Best Methods Abstract: Linda E. Levesque, McGill University. Variability of Cardiovascular Risk in Observational Studies of Nonsteroidal Antiinflammatory Drugs (NSAIDs): The Role of Calendar Time Bias

Edlavitch Award: Jeroen J. Derijks, Utrecht Institute of Pharmacoepidemiological Sciences. The Association between Antidepressant Use and Hypoglycemia in Diabetic Patients: A Nested Case-Control Study.

• Induction of ISPE Fellows (FISPE)
  Gerald A. Faich, FISPE, Chair. Fellowship & Awards Committee and ISPE Immediate Past President
  - Inductees:
    Syed Rizwanuddin Ahmad, FISPE
    Miles Braun, FISPE
    Thomas R. Einarson, FISPE
    Til Stürmer, FISPE
    Suzanne L. West, FISPE

ISPE-PDS Prizes
Presented by Brian L. Strom, FISPE, Regional Editor for the Americas, Pharmacoepidemiology & Drug Safety

Giovanni Corrao, Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials

Hilde Tobi, Small proportions: what to report for confidence

Nancy S. Breekveldt, Postma Selective prescribing of atypical antipsychotics

Dustin D. French, Benzodiazepines and injury: a risk adjusted model

Robert J. Cluxton Jr, Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio Medicaid program

ISPE Distinguished Service Award
Presented by Sean Hennessy, FISPE
  - Recipient: Frank May, FISPE

ISPE Sustained Scientific Excellence Award
Presented by Gerald A. Faich, FISPE
  - Recipient: Brian L. Strom, FISPE
  - Address by: Brian L. Strom, FISPE
    The Lessons of Experience: Selected Tidbits from a Mid-Career Academic Pharmacoepidemiologist

3:30 – 4:00PM
Break/Posters/Exhibits (PAV 4/5)
**AGENDA | Saturday, August 26**

4:00 - 5:30PM

**CONCURRENT SESSIONS**

- **SYMPOSIUM: How Can Prescribing Quality Indicators Improve Public Health [78]** (AUD 1)
  Flora M Haaijer-Ruskamp, Tony J Avery, Jerry Avorn, Bjorn Wettermark. (Netherlands)

- **Propensity Scores: Contributed Papers** (AUD 2)
  Moderators: Kenneth J. Rothman, FISPE & Alejandro Arana, FISPE

4:00PM

- The Limiting Role of the C-Statistic in the Use of Propensity Scores: Evidence from Simulation and Real Life Data [79]
  Maurille A Feudjo-Tepie, Victor A Kiri. (United Kingdom)

4:15PM

- Adjustment for Multiple Cardiovascular Risk Factors with a Summary Risk Score [80]
  Patrick G Arbogast, Hua Ding, Wayne A Ray. (United States)

4:30PM

- Estimation and Use of Propensity Scores in Case-Control and Case-Cohort Studies [81]
  Roger Mansson, Sean Hennessy, Marshall M Joffe. (United States)

5:00PM

- Comparison of Performance of Propensity Score Calibration (PSC) and Multiple Imputation (MI) To Control for Unmeasured Confounding Using an Internal Validation Study [83]
  Til Stürmer, Sebastian Schneeweiss, Kenneth J Rothman, Jerry Avorn, Robert J Glynn. (United States)

5:15PM

- Bayesian Propensity Score Analysis for Observational Data [84]
  Lawrence C McCandless, Paul Gustafson, Peter C Austin. (Canada)

**WORKSHOP: To “p” or Not To “p”? How Do ISPE Members Feel about p-Values and Statistical Testing: An ISPE Public Policy Forum [92]** (AUD 4)
  Elisabeth B Andrews, Susana Perez-Gutthann. (United States)

**Antidepressants: Contributed Papers** (AUD 6)
  Moderators: Jan Willem van der Velden, FISPE & Thomas MacDonald, FISPE

4:00PM

- Risk of Suicide during Venlafaxine and Comparator Antidepressants Treatment [85]
  Annalisa Rubino, Neil Roskell, Pat Tennis, Daniel Mines, Scott Weich, Elizabeth Andrews. (United Kingdom)

4:15PM

- Tricyclic Antidepressants and the Risk of Esophagitis [86]
  Eva M van Soest, Jeanne D Dieleman, Peter D Siersema, Miriam JCM Sturkenboom, Ernst J Kuipers. (Netherlands)

4:30PM

- The Risk of Fractures in Patients Currently or Previously Using Lithium [87]
  Ingeborg Wilting, Frank de Vries, Brahm MKS Thio, Cyrus Cooper, Eibert R Heerdink, Hubert GM Leufkens, Willem A Nolen, Antoine CG Egberts, Tjeerd P van Staa. (Netherlands)

4:45PM

- Selective Serotonin Reuptake Inhibitors and Risk of Acute Pancreatitis: A Population-Based Case-Control Study [88]
  Mette Nørgaard, Jacob Jacobsen, Christiane Casse, Lars Pedersen, Preben B Mortensen, Henrik T Sørensen. (Denmark)

5:00PM

- The Association between Antidepressant Use and Hypoglycemia in Diabetic Patients: A Nested Case-Control Study [89]
  Hieronymus J Derijks, Fred HP De Koning, Eibert R Heerdink, Robert Janknegt, Olaf H Klungel, Antoine CG Egberts. (Netherlands)

  *Student Award Recipient – Edlavitch Award*

5:15PM

- Bayesian Propensity Score Analysis for Observational Data [84]
  A Comparison of Patient Profiles of SSRI and SNRI Users [90]
  Li Wei, Thomas M MacDonald. (United Kingdom)

  continued on next page ➔
22nd ICPE  ▶  August 24–27, 2006  ▶  Lisboa Congress Centre

AGENDA  |  Saturday, August 26

4:00 - 5:30 PM

Syed R Ahmad, Gerald DalPan, June M Raine, Richard Hill, Christopher D Corsico. (United States)

5:30 - 6:30 PM

Special Interest Group - Health Services Research & Education (AUD 4)
Open to all participants

2007 Scientific Program Committee Meeting (Room 1.08)
Jean-Pierre Gregoire, Chair
Open to ISPE members.

7:30 - 11:30 PM

Evening at the Pateo Alfacinha
Sponsored by i3 Drug Safety
From the late 1800’s working people flooded into Lisbon looking for a better life. They build a new sort of town, squeezing many families into small areas, with as much privacy as possible, and with a country flavour Lisbon has never lost. Pateo Alfacinha has restored a pateo with a breath of village life and community, with its many rooms and floors linked together with the wisdom and charm of the original, and ironwork and tiles from old buildings. You will experience Portuguese music, food and wine, cheeses and other tidbits. Here you can make contact with Lisbon of hundreds of years ago. Limited seating – registration required.

Admission is by ticket only. Buses will shuttle from the Congress Centre and (ISPE) hotels to the Pateo Alfacinha beginning at 7:00PM. The last bus will depart from the Pateo Alfacinha at 11:30PM, passing by all hotels.

Cutting edge epidemiology contributing to the discovery and development of safe and effective medicines

We are a global team of epidemiologists and other professionals that brings population-based evidence on disease and treatment to influence decision-making from drug discovery through development to medical practice. By designing, analyzing, and interpreting observational information from a public health perspective we play an important role in bringing new medicines to the market. The breadth of our responsibilities includes:

- Analyzing the occurrence and distribution of diseases, including underlying disease process
- Determining the burden of illness and unmet medical need
- Exploring traditional and new risk factors for diseases
- Evaluating the effect of treatment in the real world, including beneficial effects, patterns of drug use and adverse events
- Detecting opportunities for possible new drug uses and new paths of drug development
- Understanding how genes influence disease etiology and drug safety and effectiveness

Please visit our booth at the 22nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management or our website at http://epidemiology.gsk.com, to find out more detailed information about Worldwide Epidemiology at GlaxoSmithKline.

Together we can make life better.

GlaxoSmithKline
Are you interested in registries for safety and effectiveness?

Come hear Dr. Nancy Dreyer speak on Friday, August 25 at 4:00 pm.

WEB-BASED REGISTRIES

RAPID DEVELOPMENT OF EVIDENCE

Nancy A. Dreyer, MPH, PhD is Chief of Scientific Affairs for OUTCOME, a recognized leader in post-approval strategy.

OUTCOME has designed, developed and managed more than 70 post-approval studies and registries through prospective data collection with our web-based technology and integrated IVRS, PDA and paper options.

OUTCOME’s studies include many of the largest and most well-recognized programs for disease outcomes and safety/risk management. Outcome is also a leader in Quality Improvement Programs and in 2004 received the Innovation Award from the Department of Health and Human Services.

With tens of thousands of sites and more than 2 million patients enrolled in studies powered by OUTCOME, OUTCOME provides the most widely used solutions in the post-approval market.

OUTCOME
POST-MARKETING EXCELLENCE

www.outcome.com  888-526-6700  info@outcome.com
8:00-9:00AM
- Poster Session C Set-up (PAV 4)

8:00-1:45PM
- Exhibits (PAV 5)

8:00-4:00PM
- Speaker Ready Room/AV (Rooms 1.09 + 1.14)

8:00-5:00PM
- Registration (Registration Desk/Ground Floor/Congress Centre)

9:00-10:30AM
**CONCURRENT SESSIONS**

**SYMPOSIUM: Large Simple Trials To Evaluate the Safety and Effectiveness of Medicines [93]** (AUD 1)
Robert Reynolds, Allen Mitchell, Sybil Eng, Tom MacDonald, Gerald Faich. (United States)

**Pills and Policy: Contributed Papers (AUD 2)**
Moderators: Morten Andersen & Lokje de Jong van den Berg

9:00AM
- Equal Access to Treatment? Population-Based Follow-Up of Drugs Dispensed to Patients with Acute Myocardial Infarction in Sweden [94]
  Gunilla Ringback Weitoft, Orjan Ericsson, Emil Löfroth, Måns Rosén. (Sweden)

9:15AM
- Impact of Prior Authorization on Use of Angiotensin Receptor Blockers in U.S. Medicaid Programs [95]
  Michael A Fischer, Niteesh K Choudhry, Wolfgang C Winkelmayer. (United States)

9:30AM
- Impact of Restrictive Access to Clopidogrel Following Coronary Stent Implantation on Patient Health Outcomes [96]
  Odile Sheehy, Jacques LeLorier, Stéphane Rinfret. (Canada)

9:45AM
- Assessment of Analgesic Treatment Switch Patterns Post-Rofecoxib Withdrawal [97]
  Myrthe PP Sukel, Wim G Goettsch, Susan E Borggreve, Connie Chen, Piotr Kramarz, Herve Lilliu, Ron MC Herings. (Netherlands)

10:00AM
- What Therapies Have Replaced Rofecoxib? [98]
  Mary Teeling, Kathleen Bennett, John Feely. (Ireland)

10:15AM
- Rapid Monitoring of Changes in Drug Use Following Drug Policy Changes [99]
  Colin R Dormuth, Sebastian Schneeweiss. (Canada)

**Neurological: Contributed Papers (AUD 3 & 4)**
Moderators: Susan Oliveria & Michael Lewis, FISPE

9:00AM
- Migraine and the Risk of Stroke, Asthma or Death in the United Kingdom [112]
  Claudia Becker, Gunnar Brobert, Per Almqvist, Saga Johansson, Susan S Jick, Christoph R Meier. (Switzerland)

9:15AM
- The Impact of Visual Impairment on the Risk of Depression and Mortality in the Quebec Community-Dwelling Elderly Population [113]
  Yola Moride, Marie Tournier, Ducruet Thyerry, Sophie Rochon, Andryi Moshyk. (Canada)

9:30AM
- Thiazolidinedione Use Is Associated with Lower Incidence of Alzheimer’s Disease [560]
  Donald R Miller, Benjamin G Fincke, Julie E Davidson, John G Weil. (United States)

9:45AM
- Amyloid b42-Level Lowering Non-Steroidal Anti-Inflammatory Drugs and the Risk of Alzheimer’s Disease [115]
  Mendel DM Haag, Marieke van Oijen, Frank Jan de Jong, Albert Hofman, Theo Stijnen, Bruno HCH Stricker, Monique MB Breteler. (Netherlands)

10:00AM
- Overuse of Triptans and Ergotamine and the Risk of Vasoconstrictive Complications [116]
  Elisabeth A Wammes-van der Heijden, Hamid Rahimtoola, Hubert GM Leufkens, Cees C Tijsen, Antoine CG Egberts. (Netherlands)

10:15AM
- The Concurrent Use of Cholinesterase Inhibitors and Contraindicated Medications in Patients with Alzheimer’s Disease [117]
  Alison L Supina, Amuah E Joseph, Maxwell J Colleen, Hogan B David. (Canada)
Stat Ins or Stat OUT: Contributed Papers (AUDA6)
Moderators: Kate Lapane, FISPE & Olaf Klungel

9:00 AM
Is Statin Therapy Associated with a Decreased Risk for Bleeding in Patients with Chronic Atrial Fibrillation Who Are Receiving Warfarin? A Population-Based Nested Case-Control Study [100]
James D Douketis, Maqda Melo, Chaim Bell, Muhammad M Mamdani. (Canada)

9:15 AM
Statin Therapy and Reduced Risk of Pneumonia in Elderly Patients with Diabetes [101]
Ewoudt MW van de Garde, Eelko Hak, Patrick C Souverein, Arno W Hoes, Jules MM van den Bosch, Hubert GM Leufkens. (Netherlands)

9:30 AM
Lipid-Modifying Therapy and attainment of Cholesterol Goals in Europe: The Return on Expenditure Achieved for Lipid Therapy (REALITY) Study. [102]
Eric Van Ganse, Thierry Souchet, Laurent Laforest, Eno Alemo, Glenn Davies, Stephen Gutkin, Don Yin. (France)

9:45 AM
Are All Statins Created Equal? An Analysis of Acute Coronary Syndrome Patients in Medicare [103]
Niteesh K Choudhry, Raisa Levin, Wolfgang C Winkelmayer. (United States)

10:00 AM
The Effect of Statins on Urinary Albumin Excretion (UAE) and Glomerular Filtration Rate (GFR): An RCT and an Observational Cohort Study [104]
Jarir Athobari, Auke H Brantsma, Ron T Gansevoort, Sipke T Visser, Paul E de Jong, Lolkje TW de Jong-van den Berg. (Netherlands)

10:15 AM
Statin Use in Canada: Association with Lifestyle Risk Factors and Pre-Existing CVD or Diabetes [105]
C Ineke Neutel, Norm RC Campbell. (Canada)

Adherence and Switching:
Contributed Papers (AUDA8)
Moderators: Judith Jones, FISPE & John Urquhart, FIPSE

9:00 AM
Impact of Once-Weekly Bisphosphonates on Persistence Rate and Adherence Level with Osteoporosis Therapies for Secondary Prevention [106]
Julie Bloum, Alice Dragomir, Louis-Georges Ste-Marie, Julio Cesar Fernandes, Sylvie Perreault. (Canada)

9:15 AM
Evaluation of Treatment Switching Patterns in Depression: A GPRD-Based Study [107]
Delphine Saragoussi, Sebastien Bineau, Nicolas Despiegel, Dominique Milea, Mondher Toumi, Patrice Verpillat. (France)

9:30 AM
Time to Insulin after Failure of Oral Antidiabetic Therapy in Type 2 Diabetes: A UK Population-Based Analysis [108]
Ammalisa Rubino, Lisa McQuay, Marion Kvasz, Pat Tennis. (United Kingdom)

9:45 AM
Changes in Antihypertensive Drug Use Following Educational Interventions in Primary Care [109]
Sheena O’Riordan, Fiona E Horn, Judith M Mackson, Sonia E Wutzke, John Mandryk, Lynn M Weekes. (Australia)

10:00 AM
Adherence to Statin Therapy under Drug Cost-Sharing in Patients with and without Acute MI: A Population-Based Natural Experiment [110]
Sebastian Schneeweiss, Mandy Patrick, Malcolm Maclure, Colin Dormuth, Robert Glynn. (United States)

10:15 AM
The Effects of Adherence on Anticoagulation Control with Warfarin [111]
Stephen E Kimmel, Zhen Chen, Maureen Price, Catherine S Parker, Joshua P Metlay, Jason D Christie, Colleen M Brensinger, Craig W Newcomb, Frederick F Samaha, Robert Gross. (United States)

10:30-11:00 AM
Break/Posters/Exhibits (PAV 4/5)
CONCURRENT SESSIONS

SYMPOSIUM: Do Exclusion Criteria in Pharmacoepidemiological Studies Matter? [118] (AUD 1)
Michael J Perrio, Patrick C Waller, Thomas M MacDonald, Kenneth J Rothman, Saad AW Shakir. (United Kingdom)

Drug Utilization Research, Methods, Findings and Implications: Contributed Papers (AUD 2)
Moderators: Lynn A. Bosco & Ulf Bergman, FISPE

11:00AM
Differences in Secondary Medical Prevention among Danish Patients with Peripheral Arterial Disease and Myocardial Infarction: A Population-Based Follow-Up Study [119]
Christiane Gasse, Jacob Jacobsen, Henrik T Sørensen, Erik B Schmidt, Anders C Larsen, Niels Johansen, Jørgen Videbæk, Søren P Johnsen. (Denmark)

11:15AM
Cardioprotective Drug Treatment of Elderly Type 2 Diabetics in Quebec: A Population-Based Utilization Review [120]
Caroline Sirois, Jocelyne Moisan, Jean-Pierre Gregoire. (Canada)

11:30AM
Temporal Trends in Cardiovascular Drug Use after Myocardial Infarction in the Elderly [121]
Soko Setoguchi, Jerry Avorn, Robert J Glynn, Wolfgang C Winkelmayer. (United States)

11:45AM
Factors Associated with COX-2 Usage Patterns: A Multinomial Analysis in the CADEUS Study [122]
Jeremy Jove, Jacques Benichou, Fanny Depont, Cecile Droz, Michel Amouretti, Patrick Blin, Nicholas Moore, Annie Fourrier, The CADEUS Study Team. (France)

12:00PM
Face to Face Interaction between Pharmaceutical Sales Representatives and General Practitioners: Impact on Prescribing Patterns [123]
Jens Søndergaard, Kirstin Vach, Jakob Kragstrup, Morten Andersen. (Denmark)

12:15PM
Comparison of Patient Interviews and Computerized Database for Determination of Drug Exposure in Pharmacoepidemiology: Data from the "Three-City" (3C) Study [124]
Pernelle Noize, Nicholas Moore, Nathalie Lechevallier-Michel, Annie Fourrier-Reglat, The 3C Study Group. (France)

Public Health Implications: Contributed Papers (AUD 3 & 4)
Moderator: M Levy

11:00AM
Clinical Consequences of Drug Benefit Limits [137]
John Hsu, Maggie Price, Richard Brand, Joseph Newhouse, Joseph Selby, Rita Hui, Jie Huang, Vicki Fung, Bruce Fireman. (United States)

11:15AM
A Database for Pharmacoepidemiologic Research in Portugal [138]
Zilda Mendes, José Pedro Guerreiro, Sofia Crisóstomo. (Portugal)

11:30AM
Patterns of Medication Use in U.S. Adults and Children, 2005: A Report from the Slone Survey [139]
David W Kaufman, Judith P Kelly, Lynn Rosenberg, Theresa E Anderson, Katherine Kelly, Allen A Mitchell. (United States)

11:45AM
Patient, Physician, Pharmacy and Pharmacy Benefit Design Factors Related to Generic Medication Use [140]
William H Shrank, Margaret Stedman, Susan Ettner, Dee Delapp, June Dirstein, Alan Brookhart, Michael Fischer, Jerry Avorn, Steven Asch. (United States)

12:00PM
Determinants of Hormone Replacement Therapy in Portuguese Women [141]
Raquel Lucas, Henrique Barros. (Portugal)

12:15PM
Effect of Restricted Access to Clopidogrel on Patient Health Outcomes Following Cerebrovascular Event in the Elderly [142]
Odile Sheehy, Stéphane Rinfret, Élisabeth Leroux, Jacques LeLorier. (Canada)
COX-2 and Cardiovascular Events: Contributed Papers (AUD 6)
Moderators: Mirjam CJM Sturkenboom & Jacques LeLorier, FISPE

11:00AM
Association between Cyclooxygenase-2 Selective Non-Steroidal Anti-Inflammatory Drugs and Acute Myocardial Infarction in the General Practice Research Database: Preliminary Findings [125]
Tarek A Hammad, David Graham, Judy Staffa, Cynthia Kornegay, Gerald Dal Pan. (United States)

COX-2 Selective and Non-Selective NSAIDs and the Risk of Acute Myocardial Infarction [126]
Frank Andersohn, Samy Suissa, Edeltraut Garbe. (Germany)

11:30AM
Cox-2 Inhibitors, Other NSAIDs, and the Risk of Myocardial Infarction in Three Populations in Three Countries (UK, Canada, and the US) [127]
Michael A Lewis, Donald R Miller, Elham Rahme, Dörthe Kühl-Habich, Fran Cunningham, Amir A Tahami Monfared, David W Kaufman, Lynn Rosenberg, Jaques LeLorier. (Germany)

Variability of Cardiovascular Risk in Observational Studies of Nonsteroidal AntiInflammatory Drugs (NSAIDs): The Role of Calendar Time Bias [128]
Linda L Levesque, James M Brophy, Bin Zhang. (Canada)
* Student Award – Best Methods Abstract

12:00PM
Concomitant Aspirin Use Reduces Acute Myocardial Infarction Risk in Cyclooxygenase-2 Selective and Non-Selective Nonsteroidal Anti-Inflammatory Drug Users [129]
David J Graham, Gurkirpal Singh, Huijian Wang, Alka Mithal, George Triadafilopoulos. (United States)

12:15PM
Risks and Benefits of COX-2 Inhibitors Versus Non-Selective NSAIDs: Does Their Cardiovascular Risk Exceed Their Gastrointestinal Benefit? [130]
Elham Rahme, Hacene Nedjar. (Canada)
Cancer Risk, Prevention and Treatment: Contributed Papers

Moderators: Nuno Lunet & Susan Sacks, FISPE

11:00 AM
Treatment-Related Risk Factors for Premature Menopause Following Hodgkin’s Lymphoma [131]
Marie I. De Bruin, Jeannine Huiskink, Berthe M Aleman, Floor E van Leeuwen.
(Netherlands)

11:15 AM
The Risk of Cancer with Antidiabetic Agents: Evidence from Clinical Trial and Observational Data [132]
Carol E Koro, Susan A Oliveria, Marianne Ulcickas Yood, Margaret O Sowell, Monika Stender. (United States)

11:30 AM
The Effect of Warfarin Use on the Risk of Urogenital Cancer [133]
Vicky Tagalakis, Hani Tamim, Jean-Paul Collet, Susan R Kahn, Mark Blostein, James A Hanley. (Canada)

11:45 AM
Long-Term NSAID Use and CYP2C9 Variant Alleles Protect Against Colorectal Cancer [134]
Claire Siemes, Loes E Visser, Jan-Willem W Coebergh, Ron HN van Schaik, Albert Hofman, Huib AP Pols, Bruno HCH Stricker. (Netherlands)

12:00 PM
Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis [135]
Felix M Arellano, Charles E Wentworth, Alejandro Arana, Carlos Fernandez, Carle Paul, Felix M Arellano, Carle Paul. (United States)

12:15 PM
History of Depression Predicts Early Discontinuation of Tamoxifen [136]
Thomas I Barron, Kathleen Bennett, John Feely. (Ireland)

12:30-2:00 PM
Lunch/Poster Session C/Exhibits
(PAV 4/5)

ISPE Board of Directors Luncheon
(Hotel Vila Gale Opera)
- By Invitation

2:00-3:00 PM
INVITED PLENARY (AUD 1)
Henrique de Barros, Managing Drug Risks in Public Health

3:00-4:30 PM
HOT TOPICS SESSION (AUD 1)
More Science and Less Regulatory Compliance in Postmarketing Safety
Chair: Brian Strom, FISPE

June Raine, Is Science Driving Regulatory Action or ...?

David Graham, Can We Respond to All Safety Issues with a Series of Formal Pharmacoepi Studies?

Andy Stergachis, FISPE, The IOM Report: Can We Expect More Science?

4:30-5:00 PM
The Final Word (PAV 1)
Jean-Pierre Gregoire,
Chair, 2007 Scientific Program Committee

5:00 PM
Adjournment of ICPE 2006